KRSA · XBRL financial data
Korsana Biosciences financial statements, every fiscal year
The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal years (KRSA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Revenue | 2,296 | 3,942 | 1,625 | 0 | 2,000 | 2,074 |
| Revenue from contracts with customers | 2,296 | — | — | — | — | — |
| Research and development | 56,414 | 37,636 | 31,493 | 1,515 | 286 | 959 |
| General and administrative | 28,816 | 20,620 | 14,504 | 8,132 | 5,342 | 6,088 |
| Total operating expenses | 83,561 | 59,137 | 45,997 | 12,951 | 5,628 | 7,047 |
| Operating income (loss) | (81,265) | (55,195) | (44,372) | (12,951) | (3,628) | (4,973) |
| Income tax expense (benefit) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income (loss) | (77,802) | (51,647) | (44,078) | (5,263) | (3,057) | (3,528) |
| Earnings per share, basic USD per share | — | (1.32) | (1.01) | (2.25) | (1.21) | (1.11) |
| Earnings per share, diluted USD per share | — | (1.32) | (1.01) | (2.25) | (1.21) | (1.11) |
| Weighted average shares, basic thousands of shares | — | 39,144 | 43,469 | 2,338 | 2,518 | 3,181 |
| Weighted average shares, diluted thousands of shares | — | 39,144 | 43,469 | 2,338 | 2,518 | 3,181 |
- † Share count changed about 1/16 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Balance sheet
CSVFiscal years (KRSA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 54,395 | 53,961 | 13,382 | 7,571 | 3,232 | 3,240 |
| Accounts receivable | 0 | 100 | 96 | 0 | 556 | 1,000 |
| Prepaid and other current assets | — | — | — | — | — | 461 |
| Total current assets | 58,501 | 55,457 | 14,820 | 8,024 | 4,225 | 4,635 |
| Property and equipment, net | 6,865 | 65 | 0 | 0 | 0 | 0 |
| Right-of-use asset | 43,402 | 1,402 | 1,218 | 0 | — | 0 |
| Total assets | 115,378 | 59,331 | 18,079 | 13,374 | 9,575 | 9,985 |
| Accounts payable | 1,149 | 1,828 | 2,970 | 1,198 | 390 | 508 |
| Total current liabilities | 16,952 | 11,085 | 7,627 | 2,086 | 725 | 900 |
| Lease liability, non-current | 38,933 | 0 | — | — | — | 0 |
| Total liabilities | — | — | — | — | — | 13,027 |
| Accumulated deficit | (163,429) | (215,076) | (259,154) | (264,417) | (267,492) | (271,020) |
| Total stockholders' equity | 59,493 | 48,246 | 10,452 | 11,288 | 8,850 | 9,085 |
| Total liabilities and equity | 115,378 | 59,331 | 18,079 | 13,374 | 9,575 | 9,985 |
| Common shares outstanding (cover page) thousands of shares | 34,055 | 43,410 | 43,525 | 2,710 | 2,710 | 4,330 |
- † Share count changed about 1/16 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Cash flows
CSVFiscal years (KRSA's year ends in late December)
| In thousands of dollars | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | †Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|
| Net income (loss) | (77,802) | (51,647) | (44,078) | (5,263) | (3,057) | (3,528) |
| Stock-based compensation | 14,992 | 9,611 | 6,252 | 1,067 | 625 | 441 |
| Net cash from operating activities | (72,490) | (36,517) | (40,611) | (21,245) | (4,333) | (3,314) |
| Purchases of property and equipment | 1,524 | 7 | 0 | — | — | — |
| Net cash from investing activities | 18 | 1,457 | 0 | 10,402 | 0 | — |
| Proceeds from issuing common stock | — | — | 0 | 5,000 | 0 | 1,375 |
| Net cash from financing activities | 28,090 | 30,785 | 29 | 5,024 | 0 | 3,322 |
| Net change in cash | (44,389) | (4,271) | (40,579) | (5,811) | (4,339) | 8 |
- † Share count changed about 1/16 in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
- A cell reading “year only” links to a 10-K that gives only the full year: without all three earlier quarters there is no fourth quarter to work out, and the year total is never shown as a quarter.
| Company | Cash ($K) | Revenue, quarter ($K) | Operating cash flow, quarter ($K) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Korsana Biosciences | 456,221 | not reported | (46,829)* | 45.5M | 27.5 quarters | 10-QSep 30, 2026 |
| America Great Health | 29 | 26 | 1.7* | 21.2B | — | 10-QMar 31, 2026 |
| AbbVie | 10,774,000 | 17,404,000 | 7,606,000* | 1.8B | — | 10-QSep 30, 2026 |
| Abeona Therapeutics | 56,229 | 11,380 | (17,496)* | 57.2M | 8.4 quarters | 10-QJun 30, 2026 |
| Abbott Laboratories | 4,052,000 | 13,013,000 | 1,737,000* | 1.7B | — | 10-QSep 30, 2026 |
| Arbutus Biopharma | 19,171 | 1,014 | (6,018)* | 197.8M | 15.4 quarters | 10-QJun 30, 2026 |
| Abvc Biopharma | 32 | not reported | (244)* | 26.7M | 0.4 quarters | 10-QJun 30, 2026 |
| Acadia Pharmaceuticals | 322,365 | 342,291 | 11,503* | 172.8M | — | 10-QSep 30, 2026 |
| AC Immune | 26,795 | year only | year only | 101.7M | — | 20-FDec 31, 2025 |
Not investment advice. Not affiliated with the U.S. SEC.
Data on this page was fetched . The filing on SEC.gov is the record.